Overview

Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

Status:
Withdrawn

Trial end date:
2019-02-01

Target enrollment:

Participant gender:

Summary

This is a Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing Motor Complications of Levodopa Therapy

Phase:

Phase 2

Details

Lead Sponsor:

Prexton Therapeutics

Treatments:

Levodopa